ClinicalTrials.gg
TerminatedNCT02633293Updated Dec 2, 2022Results posted

An Open Label Extension Study to Evaluate Inhaled Treprostinil in Adult PH With ILD Including CPFE

A Phase 2/3 interventional study of Inhaled Treprostinil in Pulmonary Hypertension, Interstitial Lung Disease and Combined Pulmonary Fibrosis and Emphysema, sponsored by United Therapeutics. Terminated at 92 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-12-02.

Sponsored by United Therapeutics · Phase 2/3, Interventional, and Treatment

Why this study was terminated
Inhaled treprostinil became commercially available in the US following its approval for PH-ILD

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
243
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 38 studies testing treprostinil in Hypertension, Pulmonary — 4 open to participants now, 4 under way, 1 of them phase 3. treprostinil · Hypertension, Pulmonary.

Enrollment
7th of 37
243 · median 32
Started
2016
with 2 others
Phase 2/3
2 of 38
none open now
Registered
21st of 38
by date
Lead sponsor
25 of 38
United Therapeutics

Among the 38 studies testing treprostinil in Hypertension, Pulmonary, this one is the 7th largest by enrollment of the 37 interventional ones that give a count, is one of 3 that started in 2016, is one of 2 in phase 2/3, and was the 21st registered.

Hypertension, Pulmonary

1,092 studies on the registry are indexed under Hypertension, Pulmonary; 243 are open to participants now.

Browse Hypertension, Pulmonary studies →

Open to participants now

4 of the 38 studies testing treprostinil in Hypertension, Pulmonary are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About treprostinil

treprostinil: first FDA approval 2002 (REMODULIN), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 163 Hypertension, Pulmonary studies recruiting now, 99 (61%) set no upper age limit and 26 (16%) stop at 75 or younger; 39 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies testing treprostinil in Hypertension, Pulmonary, or all of them as a file.
02

Study summary

This is a multicenter, open-label trial to evaluate the safety and efficacy of inhaled treprostinil in subjects with pre-capillary pulmonary hypertension (PH) associated with interstitial lung disease (ILD) including combined pulmonary fibrosis and emphysema (CPFE). The study will include about 266 patients who completed all required assessments in the RIN-PH-201 study at approximately 100 clinical trial centers. The study will continue Your participation in this study is voluntary and will last until you discontinue from the study or the study ends. The study will continue until each subject reaches the Week 108 visit or until inhaled treprostinil become commercially available for patients with PH associated with ILD including CPFE (whichever is sooner).

03

Conditions studied

  • Pulmonary Hypertension
  • Interstitial Lung Disease
  • Combined Pulmonary Fibrosis and Emphysema

Keywords

  • Treprostinil
  • PH
  • ILD
  • CPFE
  • 6 Minute Walk Test
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject voluntarily gives to participate in the study.
  2. The subject participated in study RIN-PH-201, remained on study drug, was compliant with RIN-PH-201 study procedures or was enrolled in study RIN-PH-201 at the time that the study was discontinued by the sponsor.
  3. Females of must be non-pregnant (as confirmed by a urine pregnancy test at Baseline) and non-lactating, and will:

    • Either abstain from intercourse (when it is in line with their preferred and usual lifestyle), or
    • Use two medically acceptable, highly-effective forms of for the duration of study, and at least 30 days after discontinuing study drug.
  4. Males must use a condom for the duration of treatment and for at least 48 hours after discontinuing study drug.

Exclusion criteria

Exclusion Criteria:

  1. The subject is pregnant or lactating.
  2. The subject was prematurely discontinued from study RIN-PH-201.
  3. The subject developed a concurrent illness or condition during the conduct of RIN-PH-201 which, in the opinion of the Investigator, would represent a risk to overall health if they enrolled in this study.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
243 participants (actual)

Study arms

  • Experimental
    Inhaled Treprostinil

    Open-label access

    Drug: Inhaled Treprostinil

Interventions

  • Inhaled treprostinil up to 15 breaths (90 mcg) four times daily

    Also known as: Tyvaso

06

What researchers measure

Primary outcomes

  1. Change in Peak 6-Minute Walk Distance (6MWD) From Baseline

    The intent of the 6MWD test is to evaluate exercise capacity associated with carrying out activities of daily living. Change in 6MWD from Baseline correlates with the current clinical standard for assessing patient functional status in the treatment of PH and is considered an objective measure of patient functional status. Subjects will be instructed to walk down a corridor at a comfortable speed as far as they can manage for 6 minutes. Distance \<500 meters suggests considerable exercise limitation; Distance 500-800 meters suggests moderate limitation; Distance \>800 meters (with no rests) suggests mild or no limitation. Peak exposure 6MWD will occur by conducting 6MWT within 10 to 60 minutes after the most recent dose of study drug dose.

    Time frame: Baseline through Week 124 in RIN-PH-202 (Combined data from parent study RIN-PH-201 [NCT02630316] and this open-label extension study RIN-PH-202)

Secondary outcomes

  1. Change in Plasma Concentration of N-terminal Pro-Brain Natriuretic Peptide (NT-proBNP) From Baseline

    The N-terminal pro-BNP (NT-proBNP) serum concentration is a useful biomarker associated with changes in right heart morphology and function. NT-proBNP serum concentration will be assessed to compare the severity of heart failure at Baseline and each visit through Week 124. Blood for NT-proBNP assessment must be drawn prior to conducting the 6-minute walk test (6MWT).

    Time frame: Baseline through Week 124 in RIN-PH-202 (Combined data from parent study RIN-PH-201 [NCT02630316] and this open-label extension study RIN-PH-202)

  2. Change in Percent Predicted Forced Vital Capacity (FVC) From Baseline

    Change in pulmonary function following inhaled treprostinil therapy will be measured by Forced Vital Capacity (FVC), calculated from a Pulmonary Function Test (PFT) performed at Baseline and Weeks 12, 48, and 108.

    Time frame: Baseline and Weeks 12, 48, and 108

07

Results

Posted Dec 2, 2022

Participant flow

Participant flow — Overall Study
MilestoneInhaled Treprostinil
Started243
Received inhaled treprostinil in rin-ph-202 (safety population)242
Completed70
Not completed173
Withdrew: Death56
Withdrew: Progressive disease12
Withdrew: Adverse event29
Withdrew: Withdrawal by subject41
Withdrew: Protocol violation1
Withdrew: Lost to follow-up1
Withdrew: Study terminated by sponsor24
Withdrew: Withdrawal by sponsor prior to dose administration1
Withdrew: Lung transplant5
Withdrew: Lack of efficacy2
Withdrew: Principal investigator terminated study site1

Outcome measures

PrimaryChange in Peak 6-Minute Walk Distance (6MWD) From Baseline

The intent of the 6MWD test is to evaluate exercise capacity associated with carrying out activities of daily living. Change in 6MWD from Baseline correlates with the current clinical standard for assessing patient functional status in the treatment of PH and is considered an objective measure of patient functional status. Subjects will be instructed to walk down a corridor at a comfortable speed as far as they can manage for 6 minutes. Distance \<500 meters suggests considerable exercise limitation; Distance 500-800 meters suggests moderate limitation; Distance \>800 meters (with no rests) suggests mild or no limitation. Peak exposure 6MWD will occur by conducting 6MWT within 10 to 60 minutes after the most recent dose of study drug dose.

Time frame:
Baseline through Week 124 in RIN-PH-202 (Combined data from parent study RIN-PH-201 [NCT02630316] and this open-label extension study RIN-PH-202)
Reported as:
Median · meters
Change in Peak 6-Minute Walk Distance (6MWD) From Baseline
metersInhaled Treprostinil
Week 41.5 (-197 to 258)
Week 85.0 (-259 to 196)
Week 129.5 (-190 to 192)
Week 1610.0 (-269 to 183)
Week 2012.0 (-189 to 169)
Week 2810.0 (-222 to 175)
Week 403.0 (-261 to 171)
Week 523.0 (-223 to 194)
Week 64-2.0 (-218 to 178)
Week 76-2.0 (-209 to 210)
Week 88-5.0 (-180 to 185)
Week 100-11.0 (-213 to 196)
Week 112-24.0 (-183 to 216)
Week 124-16.0 (-287 to 190)
SecondaryChange in Plasma Concentration of N-terminal Pro-Brain Natriuretic Peptide (NT-proBNP) From Baseline

The N-terminal pro-BNP (NT-proBNP) serum concentration is a useful biomarker associated with changes in right heart morphology and function. NT-proBNP serum concentration will be assessed to compare the severity of heart failure at Baseline and each visit through Week 124. Blood for NT-proBNP assessment must be drawn prior to conducting the 6-minute walk test (6MWT).

Time frame:
Baseline through Week 124 in RIN-PH-202 (Combined data from parent study RIN-PH-201 [NCT02630316] and this open-label extension study RIN-PH-202)
Reported as:
Median · pg/mL
Change in Plasma Concentration of N-terminal Pro-Brain Natriuretic Peptide (NT-proBNP) From Baseline
pg/mLInhaled Treprostinil
Week 8-5.10 (-9704.2 to 34,807.3)
Week 16-1.30 (-11,433.0 to 87,148.3)
Week 6410.2 (-10,280.0 to 7306.0)
Week 12431.90 (-4500.2 to 26,197.7)
SecondaryChange in Percent Predicted Forced Vital Capacity (FVC) From Baseline

Change in pulmonary function following inhaled treprostinil therapy will be measured by Forced Vital Capacity (FVC), calculated from a Pulmonary Function Test (PFT) performed at Baseline and Weeks 12, 48, and 108.

Time frame:
Baseline and Weeks 12, 48, and 108
Reported as:
Median · Percent Predicted FVC
Change in Percent Predicted Forced Vital Capacity (FVC) From Baseline
Percent Predicted FVCInhaled Treprostinil
Week 120.5 (-16 to 23)
Week 482.0 (-10 to 21)
Week 1083.0 (-13 to 13)

Adverse events

Collected over AEs were recorded throughout the course of the study from the time that each subject signed the ICF until all study assessments were completed, through the time that the study was terminated by the Sponsor (following the approval of inhaled treprostinil for use in patients with PH-ILD), up to 108 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Inhaled Treprostinil56/242 (23.1%)133/242 (55%)229/242 (94.6%)
Most frequent serious events
Showing 10 of 149
Most frequent serious events
EventInhaled Treprostinil
Acute respiratory failureRespiratory, thoracic and mediastinal disorders28/242
PneumoniaInfections and infestations21/242
Respiratory failureRespiratory, thoracic and mediastinal disorders13/242
Right ventricular failureCardiac disorders10/242
Acute kidney injuryRenal and urinary disorders9/242
Cardiac arrestCardiac disorders8/242
Fluid overloadMetabolism and nutrition disorders8/242
Interstitial lung diseaseRespiratory, thoracic and mediastinal disorders8/242
SepsisInfections and infestations7/242
DyspnoeaRespiratory, thoracic and mediastinal disorders7/242
Most frequent other events
Showing 10 of 35
Most frequent other events
EventInhaled Treprostinil
CoughRespiratory, thoracic and mediastinal disorders65/242
DyspnoeaRespiratory, thoracic and mediastinal disorders63/242
HeadacheNervous system disorders45/242
DiarrhoeaGastrointestinal disorders37/242
DizzinessNervous system disorders36/242
Upper respiratory tract infectionInfections and infestations34/242
NauseaGastrointestinal disorders32/242
FatigueGeneral disorders32/242
PneumoniaInfections and infestations30/242
Acute respiratory failureRespiratory, thoracic and mediastinal disorders30/242

Baseline characteristics

Safety Population

Age, Continuous
Age, Continuous(years)Inhaled Treprostinil
Median70.0 (27 to 90)
Sex: Female, Male
Sex: Female, Male(Participants)Inhaled Treprostinil
Female116
Male126
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Inhaled Treprostinil
Hispanic or Latino17
Not Hispanic or Latino224
Unknown or Not Reported1
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Inhaled Treprostinil
American Indian or Alaska Native3
Asian8
Native Hawaiian or Other Pacific Islander0
Black or African American53
White178
More than one race0
Unknown or Not Reported0
Time Since Diagnosis
Time Since Diagnosis(years)Inhaled Treprostinil
Median0.51 (0.3 to 13.3)
Current Diagnosis
Current Diagnosis(Participants)Inhaled Treprostinil
Idiopathic interstitial pneumonia108
Chronic hypersensitivity pneumonitis13
Occupational lung disease5
Combined pulmonary fibrosis and emphysema59
Connective tissue disease57
6-Minute Walk Distance (6MWD)
6-Minute Walk Distance (6MWD)(meters)Inhaled Treprostinil
Median270.0 (24 to 549)
N-terminal Pro-brain Natriuretic Peptide (NT-proBNP)
N-terminal Pro-brain Natriuretic Peptide (NT-proBNP)(pg/mL)Inhaled Treprostinil
Median465.70 (10.2 to 92,852)

3 further baseline measures are reported on the registry.

08

Study locations

92 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35294, United States
  • IMC-Diagnostic & Medical Clinic
    Mobile, Alabama 36604, United States
  • Arizona Pulmonary Specialists, Ltd.
    Phoenix, Arizona 85012, United States
  • University of Arizona
    Tucson, Arizona 85724, United States
  • Cedars-Sinai Medical Center
    Beverly Hills, California 90211, United States
  • University of California, San Francisco-Fresno
    Fresno, California 93701, United States
  • University of California San Diego
    La Jolla, California 92093, United States
  • VA Long Beach Healthcare System
    Long Beach, California 90822, United States
  • University of Southern California
    Los Angeles, California 90033, United States
  • Department of Veterans Affairs Greater Los Angeles Healthcare System
    Los Angeles, California 90073, United States
  • Pacific Pulmonary Medical Group
    Riverside, California 92505, United States
  • University of California Davis Medical Center
    Sacramento, California 95817, United States
  • Kaiser Permanente
    San Francisco, California 94115, United States
  • University of Colorado Hospital - Cardiac and Vascular Center
    Aurora, Colorado 80045, United States
  • National Jewish Health
    Denver, Colorado 80206, United States
  • Georgetown University Hospital
    Washington, District of Columbia 20007, United States
  • MedStar Heart & Vascular Institute
    Washington, District of Columbia 20010, United States
  • Florida Lung, Asthma & Sleep Specialists, P.A.
    Celebration, Florida 34747, United States
  • St. Francis Sleep, Allergy and Lung Institute
    Clearwater, Florida 33765, United States
  • University of Florida Clinical Research Center
    Gainesville, Florida 32610, United States
  • University of Florida College of Medicine, Jacksonville
    Jacksonville, Florida 32209, United States
  • Mayo Clinic Jacksonville
    Jacksonville, Florida 32224, United States
  • St. Vincent's Lung, Sleep, and Critical Care Specialists
    Jacksonville, Florida 33204, United States
  • University of Miami
    Miami, Florida 33136, United States
  • Florida Hospital
    Orlando, Florida 32804, United States
  • University of South Florida
    Tampa, Florida 33606, United States
  • Cleveland Clinic Florida
    Weston, Florida 33331, United States
  • The Emory Clinic
    Atlanta, Georgia 30322, United States
  • Piedmont - Georgia Lung Associates
    Austell, Georgia 30106, United States
  • Wellstar Medical Group
    Marietta, Georgia 30060, United States
  • Northwestern University
    Chicago, Illinois 60611, United States
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
  • University of Illinois at Chicago Hospital
    Chicago, Illinois 60612, United States
  • University of Chicago Medical Center
    Chicago, Illinois 60637, United States
  • Loyola University Medical Center
    Maywood, Illinois 60153, United States
  • Indiana University Hospital
    Indianapolis, Indiana 46202, United States
  • Community Heart and Vascular Hospital
    Indianapolis, Indiana 46250, United States
  • St. Vincent Medical Group, Inc.
    Indianapolis, Indiana 46260, United States
  • University of Iowa Hospitals & Clinics
    Iowa City, Iowa 52242, United States
  • University of Kansas Medical Center
    Kansas City, Kansas 66160, United States
  • University of Louisville Physicians Outpatient Center
    Louisville, Kentucky 40202, United States
  • Louisiana State University Health Sciences Center New Orleans
    New Orleans, Louisiana 70112, United States
  • Maine Medical Center
    South Portland, Maine 04106, United States
  • University of Maryland Medical Center
    Baltimore, Maryland 21201, United States
  • Johns Hopkins University
    Baltimore, Maryland 21205, United States
  • Tufts Medical Center
    Boston, Massachusetts 02111, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Brigham and Women's Hospital
    Boston, Massachusetts 02115, United States
  • Spectrum Health Medical Center
    Grand Rapids, Michigan 49503, United States
  • University of Minnesota
    Minneapolis, Minnesota 55455, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • University of Mississippi Medical Center
    Jackson, Mississippi 39216, United States
  • Saint Luke's Hospital of Kansas City
    Kansas City, Missouri 64111, United States
  • Washington University Hospital
    Saint Louis, Missouri 63110, United States
  • The University of New Mexico
    Albuquerque, New Mexico 87131, United States
  • Albany Medical College
    Albany, New York 12208, United States
  • New York Methodist Hospital
    Brooklyn, New York 11215, United States
  • Northwell Health
    New Hyde Park, New York 11040, United States
  • NYU Langone Medical Center
    New York, New York 10016, United States
  • The Mount Sinai Hospital
    New York, New York 10029, United States
  • Weill Cornell Medical Center
    New York, New York 10065, United States
  • University of North Carolina at Chapel Hill
    Chapel Hill, North Carolina 27599, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • Pinehurst Medical Clinic, Inc.
    Pinehurst, North Carolina 28374, United States
  • The Carl and Edyth Lindner Research Center at The Christ Hospital
    Cincinnati, Ohio 45219, United States
  • University of Cincinnati Health
    Cincinnati, Ohio 45267, United States
  • University Hospitals Cleveland Medical Center
    Cleveland, Ohio 44106, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • The Ohio State University Medical Center
    Columbus, Ohio 43221, United States
  • Integris Baptist Medical Center
    Oklahoma City, Oklahoma 73112, United States
  • Hospital of University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • Allegheny General Hospital
    Pittsburgh, Pennsylvania 15212, United States
  • University of Pittsburgh Medical Center
    Pittsburgh, Pennsylvania 15213, United States
  • AnMed Health Pulmonary and Sleep Medicine
    Anderson, South Carolina 29621, United States
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
  • Statcare Pulmonary Consultants
    Knoxville, Tennessee 37919, United States
  • Baylor University Medical Center at Dallas
    Dallas, Texas 75246, United States
  • UT Southwestern Medical Center
    Dallas, Texas 75390, United States
  • Texas Tech University Health Sciences Center
    El Paso, Texas 79905, United States
  • Houston Methodist
    Houston, Texas 77030, United States
  • Michael E. DeBakey VA Medical Center
    Houston, Texas 77030, United States
  • The University of Texas Health Science Center at Houston
    Houston, Texas 77030, United States
  • The University of Texas Health Science Center at San Antonio
    San Antonio, Texas 78229, United States
  • University of Vermont, Vermont Lung Center
    Colchester, Vermont 05446, United States
  • Inova Fairfax Hospital
    Fairfax, Virginia 22042, United States
  • Sentara Cardiovascular Research Institute
    Norfolk, Virginia 23507, United States
  • Pulmonary Associates of Richmond
    Richmond, Virginia 23229, United States
  • University of Washington Medical Center
    Seattle, Washington 98195, United States
  • University of Wisconsin School of Medicine and Public Health
    Madison, Wisconsin 53792, United States
  • Aurora St. Luke's Medical Center
    Milwaukee, Wisconsin 53215, United States
  • Medical College of Wisconsin/Froedtert Hospital
    Milwaukee, Wisconsin 53226, United States
  • Alliance Cardio Pulmonary Research Group, Inc.
    Guaynabo, 00968, Puerto Rico
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2016 to primary completion in Aug 2021, 58 months.

Results were first posted in Dec 2022, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 11, 2015
First posted
Dec 17, 2015
StartActual
Sep 15, 2016
Primary completionActual
Aug 1, 2021
CompletionActual
Aug 1, 2021
Results first posted
Dec 2, 2022
Last update
Dec 2, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 2, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02633293
Responsible party
Sponsor
First posted
Dec 17, 2015
Start date
Sep 15, 2016
Primary completion
Aug 1, 2021
Completion
Aug 1, 2021
Results posted
Dec 2, 2022
Last update
Dec 2, 2022

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Treprostinil

Start the discussion